For the twelve months ended Sep 30, 2026, Guardian Pharmacy Services Inc. reported $1.46B of revenue and $74.77M of net income.
GRDN revenue was $371.07M in fiscal Q3 2026 (ended Sep 30, 2026), down 1.7% from a year earlier and up 5.5% from the prior quarter. For the full fiscal 2025 it was $1.45B, up 17.9% from fiscal 2024.
GRDN net income was $18.68M in fiscal Q3 2026 (ended Sep 30, 2026), up 90.3% from a year earlier and down 14.6% from the prior quarter. For the full fiscal 2025 it was $49.22M, compared with -$110.05M in fiscal 2024.
GRDN diluted EPS was $0.29 in fiscal Q3 2026 (ended Sep 30, 2026), up 93.3% from a year earlier.
GRDN free cash flow was $34.10M in fiscal Q4 2025 (ended Dec 31, 2025), up 69.8% from a year earlier and up 41.1% from the prior quarter. For the full fiscal 2025 it was $86.84M, up 100.8% from fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Revenue | $1.45B | $1.23B |
| Cost of revenue | $1.16B | $984.04M |
| Gross profit | $292.72M | $244.37M |
| Selling, general and admin | $220.02M | $307.29M |
| Operating income | $72.70M | -$62.92M |
| Interest expense | $665.0K | $3.28M |
| Pre-tax income | $73.42M | -$66.48M |
| Income tax | $24.46M | $4.56M |
| Net income | $49.22M | -$110.05M |
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $65.62M | $4.66M |
| Receivables | $101.61M | $97.15M |
| Inventory | $43.36M | $40.55M |
| Current assets | $221.63M | $151.99M |
| Goodwill | $79.74M | $69.30M |
| Total assets | $412.66M | $320.81M |
| Current liabilities | $160.70M | $144.12M |
| Total debt | $0 | $0 |
| Total liabilities | $194.73M | $170.83M |
| Shareholders' equity | $217.92M | $149.98M |
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | $100.25M | $57.96M |
| Capital expenditures | $13.42M | $14.71M |
| Free cash flow | $86.84M | $43.25M |
| Investing cash flow | -$32.23M | -$30.41M |
| Financing cash flow | -$7.07M | -$23.64M |
| Stock-based compensation | $13.85M | $131.49M |
| Depreciation and amortization | $22.34M | $19.77M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $371.07M | $351.77M | $336.60M | $397.62M | $377.43M | $344.33M | $329.31M | $338.57M | $314.39M | $300.04M | $275.41M |
| Cost of revenue | $285.85M | $271.72M | $260.29M | $312.11M | $302.71M | $276.19M | $264.96M | $271.46M | $253.51M | $238.75M | $220.31M |
| Gross profit | $85.22M | $80.04M | $76.31M | $85.50M | $74.72M | $68.15M | $64.35M | $67.10M | $60.88M | $61.29M | $55.10M |
| Selling, general and admin | $60.16M | $59.40M | $58.63M | $54.74M | $58.37M | $55.57M | $51.34M | $50.35M | $165.49M | $44.28M | $47.17M |
| Operating income | $25.06M | $20.64M | $17.68M | $30.76M | $16.35M | $12.58M | $13.01M | $16.75M | -$104.61M | $17.00M | $7.93M |
| Interest expense | $177.0K | $154.0K | $154.0K | $163.0K | $160.0K | $172.0K | $170.0K | $421.0K | $1.03M | $1.07M | $765.0K |
| Pre-tax income | $25.98M | $29.79M | $18.29M | $31.10M | $16.63M | $12.59M | $13.11M | $16.22M | -$105.64M | $15.85M | $7.09M |
| Income tax | $6.86M | $7.67M | $4.75M | $9.83M | $7.04M | $3.76M | $3.83M | $4.38M | $176.0K | $0 | $0 |
| Net income | $18.68M | $21.87M | $13.29M | $20.92M | $9.82M | $9.03M | $9.45M | $11.94M | -$121.99M | $15.85M | $7.09M |
| EPS, basic | $0.29 | - | - | - | $0.16 | - | - | - | - | - | - |
| EPS, diluted | $0.29 | - | - | - | $0.15 | - | - | - | - | - | - |
| Diluted shares | 63.9M | - | - | - | 63.4M | - | - | - | - | - | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $119.66M | $89.81M | $64.89M | $65.62M | $36.49M | $18.82M | $14.00M | $4.66M | $37.22M | $1.54M | $174.0K |
| Receivables | $107.68M | $103.77M | $111.70M | $101.61M | $106.19M | $94.13M | $97.41M | $97.15M | $90.94M | - | - |
| Inventory | $57.05M | $50.44M | $47.16M | $43.36M | $47.86M | $44.16M | $43.43M | $40.55M | $45.22M | - | - |
| Current assets | $294.82M | $254.67M | $235.18M | $221.63M | $198.28M | $170.46M | $166.04M | $151.99M | $180.26M | - | - |
| Goodwill | $81.95M | $79.74M | $79.74M | $79.74M | $79.57M | $76.16M | $69.30M | $69.30M | $68.42M | - | - |
| Total assets | $491.78M | $443.58M | $426.94M | $412.66M | $390.04M | $356.33M | $334.00M | $320.81M | $348.03M | - | - |
| Current liabilities | $179.09M | $154.04M | $160.54M | $160.70M | $161.95M | $143.99M | $145.30M | $144.12M | $158.32M | - | - |
| Long-term debt | - | - | - | - | - | - | - | - | $28.66M | - | - |
| Total debt | - | - | - | $0 | - | - | - | $0 | $28.66M | - | - |
| Total liabilities | $212.06M | $185.94M | $194.52M | $194.73M | $194.54M | $176.66M | $170.78M | $170.83M | $214.13M | - | - |
| Shareholders' equity | $279.72M | $257.64M | $232.42M | $217.92M | $195.50M | $179.67M | $163.22M | $149.98M | $133.90M | $57.21M | $56.57M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $43.37M | $30.02M | $6.06M | $34.60M | $28.17M | $19.94M | $17.55M | $22.34M | -$2.16M | $29.13M | $8.65M |
| Capital expenditures | - | - | - | $495.0K | $4.00M | - | - | $2.25M | $2.22M | - | - |
| Free cash flow | - | - | - | $34.10M | $24.17M | - | - | $20.09M | -$4.38M | - | - |
| Investing cash flow | -$10.90M | -$4.31M | -$4.75M | -$4.71M | -$8.97M | -$13.00M | -$5.54M | -$6.62M | -$7.08M | -$13.10M | -$3.60M |
| Financing cash flow | -$2.62M | -$805.0K | -$2.04M | -$758.0K | -$1.53M | -$2.11M | -$2.67M | -$48.27M | $44.93M | -$14.66M | -$5.63M |
| Share repurchases | - | - | - | - | $0 | - | - | - | - | - | - |
| Stock-based compensation | $2.73M | $2.93M | $1.86M | $1.08M | $4.36M | $4.45M | $3.97M | $3.46M | $122.36M | -$272.0K | $5.95M |
| Depreciation and amortization | $5.93M | $5.81M | $5.98M | $5.74M | $5.84M | $5.49M | $5.27M | $5.15M | $4.99M | $4.87M | $4.75M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -1.7% | 2.2% | 2.2% | 17.4% | 20.0% | 14.8% | 19.6% | - | - | - | - |
| Net income growth, YoY | 90.3% | 142.2% | 40.7% | 75.2% | - | -43.0% | 33.2% | - | - | - | - |
| EPS growth, YoY | 93.3% | - | - | - | - | - | - | - | - | - | - |
| Gross margin | 23.0% | 22.8% | 22.7% | 21.5% | 19.8% | 19.8% | 19.5% | 19.8% | 19.4% | 20.4% | 20.0% |
| Operating margin | 6.8% | 5.9% | 5.3% | 7.7% | 4.3% | 3.7% | 3.9% | 4.9% | -33.3% | 5.7% | 2.9% |
| Net margin | 5.0% | 6.2% | 3.9% | 5.3% | 2.6% | 2.6% | 2.9% | 3.5% | -38.8% | 5.3% | 2.6% |
| Free cash flow margin | - | - | - | 8.6% | 6.4% | - | - | 5.9% | -1.4% | - | - |
| Current ratio | 1.65 | 1.65 | 1.46 | 1.38 | 1.22 | 1.18 | 1.14 | 1.05 | 1.14 | - | - |
| Debt to equity | - | - | - | 0.00 | - | - | - | 0.00 | 0.21 | - | - |
Source: XBRL data Guardian Pharmacy Services Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GRDN | $1.46B | +4.9% | $74.77M | 5.1% | $2.69B |
| CVS | $420.61B | +6.7% | $11.07B | 2.6% | $107.28B |
| PETS | $168.86M | -20.3% | -$29.28M | -17.3% | $26.4M |
| YI | CN¥12.56B | -12.8% | -CN¥66.39M | -0.5% | $25.5M |
| RDGT | $132.16M | +10.2% | -$1.25M | -0.9% | $3.6M |